tiprankstipranks
Trending News
More News >
Chemours Company (CC)
:CC
Advertisement

Chemours Company (CC) AI Stock Analysis

Compare
1,368 Followers

Top Page

CC

Chemours Company

(NYSE:CC)

Rating:49Neutral
Price Target:
$12.50
▼(-1.03% Downside)
The overall stock score is primarily impacted by financial challenges, including high leverage and negative cash flow. While the earnings call provided some positive insights, operational risks and a high P/E ratio weigh on the stock's attractiveness. The technical analysis suggests potential stabilization, but the stock remains under pressure.
Positive Factors
Growth and Demand
Management expects growth driven by HFOs and regulatory changes that will increase demand for their products.
Market Performance
Chemours is expected to outperform the market with attractive longer-term options in its APM and TSS businesses and cost savings in the TT business.
Negative Factors
Earnings Pressure
The stock has come under pressure as investors questioned the earnings trajectory in TSS.
Liability Constraints
Chemours has a liability-sharing deal with DuPont and Corteva, which might constrain the company.
Profitability Challenges
Chemours' earnings per share estimates have been revised downward, indicating potential challenges in profitability.

Chemours Company (CC) vs. SPDR S&P 500 ETF (SPY)

Chemours Company Business Overview & Revenue Model

Company DescriptionThe Chemours Company (CC) is a global leader in chemical solutions, specializing in the production of titanium technologies, fluoroproducts, and chemical solutions. The company operates through three main segments: Titanium Technologies, which supplies titanium dioxide pigment for coatings, plastics, and laminates; Thermal & Specialized Solutions, which produces refrigerants and propellants; and Advanced Performance Materials, focused on high-performance polymers. Chemours is committed to innovation, sustainability, and operational excellence, serving a diverse range of industries including automotive, electronics, energy, and construction.
How the Company Makes MoneyChemours generates revenue primarily through the sale of its specialized chemical products across its three main business segments. The Titanium Technologies segment is a significant revenue driver, providing titanium dioxide used in a variety of applications such as coatings and plastics. The Thermal & Specialized Solutions segment contributes through the sale of refrigerants and propellants, which are essential in air conditioning and refrigeration industries. The Advanced Performance Materials segment earns by supplying high-performance polymers used in demanding applications like automotive and electronics. Chemours' revenue is bolstered by strategic partnerships and long-term supply agreements with major industrial customers, as well as its focus on innovation and sustainability that meets evolving regulatory and market demands.

Chemours Company Earnings Call Summary

Earnings Call Date:Aug 05, 2025
(Q1-2025)
|
% Change Since: 0.00%|
Next Earnings Date:Oct 22, 2025
Earnings Call Sentiment Neutral
The earnings call presented both positive and negative aspects. While there were strong performances in the TSS business and strategic advancements like the Navin Fluorine agreement, there were significant challenges including decreased EBITDA, pricing pressures in the TT segment, and a notable dividend reduction.
Q1-2025 Updates
Positive Updates
Strong Performance in TSS Business
The TSS business exceeded expectations with a 40% year-over-year net sales increase in Opteon refrigerants driven by increased demand for blend. Margins were driven to 30% due to strong contributions from Opteon sales.
Strategic Agreement with Navin Fluorine
Chemours announced a strategic agreement with Navin Fluorine to produce Opteon 2-phase emergent cooling fluid, aimed at addressing data cooling center needs created by AI and next-generation chips.
Successful Mitigation of Tariff Impacts
Chemours has effectively mitigated tariff exposures, particularly in the TSS segment, by leveraging supply chain flexibility and sourcing strategies.
Improved Cash Flow Outlook
Operating cash outflows improved to $112 million from $290 million in the same quarter last year, with expectations for free cash flow to be solidly positive for the full year.
Negative Updates
Decreased Adjusted EBITDA and Net Income
Adjusted EBITDA decreased to $166 million from $191 million in the prior year, and Chemours reported a net loss of $4 million compared to net income of $54 million in the previous year.
Pricing Pressure in TT Segment
The TT segment faced a 4% price decline due to regional pricing dynamics and additional costs from plant downtime, leading to a 28% decrease in adjusted EBITDA.
Challenges in APM Segment
The APM segment saw a 3% decrease in net sales due to weakness in cyclical end markets and unfavorable currency movements.
Dividend Reduction
Chemours announced a 65% reduction in its quarterly dividend, reflecting a strategic shift in capital allocation priorities.
Company Guidance
During the first quarter of 2025, The Chemours Company reported a strong 40% year-over-year increase in net sales for its Opteon refrigerants, driven by heightened demand for refrigerant blends as stationary OEMs ramp up inventories in anticipation of the 2025 U.S. AMAX transition mandate. Despite experiencing a full site outage in January due to third-party utility issues, the company managed to maintain its ability to meet customer orders, thanks to a rapid recovery effort. Chemours achieved a 30% margin in TSS, aided by a 40% capacity expansion at its Corpus Christi site. In TT, a 12% sequential sales increase was noted in Western markets, with Chemours benefiting from fair trade regulations. Although facing challenges from Chinese TiO2 dumping, the company expects a reduction in Chinese production in 2025 due to regulatory pressures and overcapacity. In APM, despite market softness, the segment improved its adjusted EBITDA margin by 1 percentage point to 11%, aided by cost reductions. The company also announced a 65% reduction in its quarterly dividend to enhance balance sheet flexibility and support strategic growth initiatives.

Chemours Company Financial Statement Overview

Summary
Chemours Company faces substantial financial challenges, with declining revenue and low profit margins. The balance sheet reveals high leverage with a debt-to-equity ratio of 7.57, and cash flow issues are evident with negative free cash flow growth.
Income Statement
55
Neutral
The company's revenue has shown a slight decline in the TTM compared to the previous year, with a revenue growth rate of 0.33%. Gross profit margin stands at 19.00%, and net profit margin is a low 0.53%, indicating challenges in maintaining profitability. The EBIT margin is 7.19%, while the EBITDA margin is 11.03%, reflecting modest operational efficiency.
Balance Sheet
45
Neutral
The balance sheet reveals a high debt-to-equity ratio of 7.57, indicating significant leverage and potential financial risk. Return on equity is low at 5.35%, suggesting limited profitability relative to shareholder equity. The equity ratio is 7.83%, highlighting a low proportion of equity financing.
Cash Flow
30
Negative
The cash flow statement shows negative free cash flow growth, with free cash flow declining significantly. The operating cash flow to net income ratio is negative, indicating operational cash flow challenges. Free cash flow to net income ratio is also negative, reflecting cash flow difficulties.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue5.88B5.78B6.03B6.79B6.34B4.97B
Gross Profit1.07B1.15B1.31B1.62B1.38B1.07B
EBITDA237.00M692.00M197.00M1.20B1.21B767.00M
Net Income-420.00M86.00M-238.00M578.00M608.00M219.00M
Balance Sheet
Total Assets7.49B7.51B8.25B7.64B7.55B7.08B
Cash, Cash Equivalents and Short-Term Investments502.00M713.00M1.20B1.10B1.45B1.10B
Total Debt244.00M4.36B4.30B3.81B3.93B4.28B
Total Liabilities7.25B6.91B7.51B6.53B6.47B6.27B
Stockholders Equity237.00M604.00M737.00M1.11B1.08B813.00M
Cash Flow
Free Cash Flow-35.00M-993.00M186.00M447.00M543.00M540.00M
Operating Cash Flow277.00M-633.00M556.00M754.00M820.00M807.00M
Investing Cash Flow-310.00M-353.00M-229.00M-284.00M220.00M-234.00M
Financing Cash Flow-26.00M-36.00M172.00M-685.00M-560.00M-449.00M

Chemours Company Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price12.63
Price Trends
50DMA
12.05
Positive
100DMA
12.10
Positive
200DMA
15.01
Negative
Market Momentum
MACD
0.02
Positive
RSI
48.33
Neutral
STOCH
26.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CC, the sentiment is Neutral. The current price of 12.63 is below the 20-day moving average (MA) of 13.37, above the 50-day MA of 12.05, and below the 200-day MA of 15.01, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 48.33 is Neutral, neither overbought nor oversold. The STOCH value of 26.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CC.

Chemours Company Risk Analysis

Chemours Company disclosed 39 risk factors in its most recent earnings report. Chemours Company reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Chemours Company Peers Comparison

Overall Rating
UnderperformOutperform
Sector (58)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Neutral
$3.13B26.465.09%3.16%3.28%1.69%
63
Neutral
$7.05B8.6214.52%5.38%1.60%-3.97%
58
Neutral
HK$16.52B4.18-4.93%4.58%-5.74%-81.55%
58
Neutral
$2.02B74.951.55%2.08%-5.45%-87.13%
57
Neutral
$3.18B-28.05%2.00%-4.31%-1421.83%
53
Neutral
$8.03B-8.66%2.39%-33.05%-97.63%
49
Neutral
$1.89B59.33-87.50%6.63%-0.68%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CC
Chemours Company
12.63
-4.71
-27.16%
ALB
Albemarle
68.25
-11.91
-14.86%
EMN
Eastman Chemical
61.39
-30.68
-33.32%
IOSP
Innospec
80.73
-26.95
-25.03%
AVNT
Avient
34.18
-9.65
-22.02%
SSL
Sasol
4.97
-2.19
-30.59%

Chemours Company Corporate Events

Legal Proceedings
Chemours Agrees to $875M Settlement with New Jersey
Negative
Aug 4, 2025

On August 3, 2025, Chemours, Corteva, and DuPont agreed to a proposed Judicial Consent Order with the State of New Jersey to resolve all pending environmental claims, including PFAS contamination, related to their operating sites and statewide issues. The settlement involves a $875 million payment over 25 years, with Chemours responsible for 50% of the payments. The agreement also includes mechanisms for future remediation funding and establishes a Reserve Fund for financial security. Additionally, Chemours entered into an agreement to sell its rights to $150 million in insurance proceeds related to PFAS claims to DuPont and Corteva.

The most recent analyst rating on (CC) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Chemours Company stock, see the CC Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 06, 2025